Guowei Kim

Dr. Guowei Kim

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
VKVikrant Kumar
Vikrant Kumar
KRKalpana Ramnarayanan
Kalpana Ramnarayanan
RSRaghav Sundar
Raghav Sundar
NPNisha Padmanabhan
Nisha Padmanabhan
SSSupriya Srivastava
Supriya Srivastava
PTPatrick Tan
Patrick Tan
Gastric cancer heterogeneity represents a barrier to disease management. We generated a comprehensive single-cell atlas of gastric cancer (>200,000 cells) comprising 48 samples from 31 patients across clinical stages and histologic subtypes. We identified 34 distinct cell-lineage states including novel rare cell populations. Many lineage states exhibited distinct cancer-associated expression profiles, individually contributing to a combined tumor-wide molecular collage. We observed increased plasma cell proportions in diffuse-type tumors associated with epithelial-resident KLF2 and stage-wise accrual of cancer-associated fibroblast subpopulations marked by high INHBA and FAP coexpression. Single-cell comparisons between patient-derived organoids (PDO) and primary tumors highlighted inter- and intralineage similarities and differences, demarcating molecular boundaries of PDOs as experimental models. We complemented these findings by spatial transcriptomics, orthogonal validation in independent bulk RNA-sequencing cohorts, and functional demonstration using in vitro and in vivo models. Our results provide a high-resolution molecular resource of intra- and interpatient lineage states across distinct gastric cancer subtypes. Significance: We profiled gastric malignancies at single-cell resolution and identified increased plasma cell proportions as a novel feature of diffuse-type tumors. We also uncovered distinct cancer-associated fibroblast subtypes with INHBA–FAP-high cell populations as predictors of poor clinical prognosis. Our findings highlight potential origins of deregulated cell states in the gastric tumor ecosystem. This article is highlighted in the In This Issue feature, p. 587

25 February 2019 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
IWIan Jun Yan Wee
Ian Jun Yan Wee
NSNicholas Li-Xun Syn
Nicholas Li-Xun Syn
ASAsim Shabbir
Asim Shabbir
GKGuowei Kim
Guowei Kim
Jimmy Bok-Yan SoJimmy Bok-Yan So
Jimmy Bok-Yan So

4 November 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
GKGuowei Kim
Guowei Kim
HTHon Lyn Tan
Hon Lyn Tan
RSRaghav Sundar
Raghav Sundar
BLBettina Lieske
Bettina Lieske
CCCheng Ean Chee
Cheng Ean Chee
JSJimmy Bok Yan So
Jimmy Bok Yan So
Purpose: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel laparoscopic, intraperitoneal chemotherapy delivery technique aiming to improve drug distribution and tissue penetration to treat peritoneal metastases. Thus far, PIPAC oxaliplatin is conducted at an arbitrary dose of 92 mg/m2. We conducted a phase I study to establish safety and tolerability. Patients and Methods: We used a 3+3 dose-escalation design of PIPAC oxaliplatin for patients with peritoneal metastases from gastrointestinal tumors, after failure of at least first-line chemotherapy. Dose levels were planned at 45, 60, 90, and 120 mg/m2. Results: This study included 16 patients with 24 PIPAC procedures (8 gastric; 5 colorectal; and 1 gallbladder, pancreas, and appendix cancer each). Median age and peritoneal cancer index (PCI) score were 62 years and 17, respectively. Two patients developed pancreatitis (grade 2 and 3) at 45 mg/m2, necessitating cohort expansion. Another patient developed grade 2 pancreatitis at 90 mg/m2. There were no other dose-limiting toxicities, and the highest-dose cohort (120 mg/m2) tolerated PIPAC well. Pharmacokinetic analyses demonstrated good linearity between dose and maximum concentration (r2 = 0.95) and AUC (r2 = 0.99). On the basis of RECIST, 62.5% and 50% had stable disease after one and two PIPAC procedures, respectively. A total of 8 patients underwent two PIPAC procedures, with improvement of median PCI and peritoneal regression grade score from 15 to 12 and 2.5 to 2.0, respectively. Conclusions: The recommended phase II dose is 120 mg/m2. Future studies should further delineate the efficacy and role of PIPAC oxaliplatin for peritoneal metastases. See related commentary by de Jong et al., p. 1830

1 June 2019 in Annals of Surgery
Verified
Journal Article
Closed access
NSNicholas L. Syn
Nicholas L. Syn
IWIan Wee
Ian Wee
ASAsim Shabbir
Asim Shabbir
GKGuowei Kim
Guowei Kim
JSJimmy Bok-Yan So
Jimmy Bok-Yan So
Objective: The aim of the study was to assess the impact of pouch reconstruction on perioperative outcomes, postprandial symptoms, nutritional and anthropometric parameters, and overall quality of life after total gastrectomy for gastric malignancy. Summary Background Data: The short-term perioperative risks and longer term functional value of creating a small-bowel reservoir after total gastrectomy are contended. Methods: A search for randomized and non-randomized studies comparing reconstruction with or without a pouch was conducted. Treatment effects were computed using pairwise random-effects meta-analysis and meta-regression, and the systematic review was conducted in accordance with PRISMA and MOOSE guidelines. Results: A total of 17 randomized trials and 8 observational studies involving 1621 participants were included. Pouch creation is associated with an increased operation time [259.3 vs 235.8 min; weighted mean difference (WMD) 23.5, 95% confidence interval (CI) 9.8–37.2], but not hospitalization duration. There was no difference in overall postsurgical complications, including anastomotic leak and abdominal abscess. Pouch formation markedly reduces the risk of dumping syndrome at 3 to 6 months [8.1% vs 32.4%; risk ratios (RR) 0.36, 95% CI, 0.21–0.60] and 12 to 24 months (2.8% vs 23.6%; RR 0.27, 95% CI, 0.16–0.46). The functional advantages of pouch reconstruction persist at 1 to 2 years, with aggregated data indicating considerably lower risks of esophagitis and heartburn (63% relative reduction), dumping syndrome (73% relative reduction), and food intake disturbance (50% relative reduction). At 12 to 24 months, albumin levels (40.5 vs 37.9 g/L; WMD 2.59, 95% CI, 1.35–3.84) and body mass index (22.2 vs 20.9 kg/m2; WMD 1.28, 95% CI, 0.61–1.94) are significantly higher among participants with a pouch. Conclusions: Pouch creation improves long-term functional and nutritional outcomes after total gastrectomy, without greater perioperative morbidity.

29 August 2018 in Pleura and Peritoneum
Verified
Journal Article
Open access
PDF file
GKGuowei Kim
Guowei Kim
HTHon Lyn Tan
Hon Lyn Tan
ECElya Chen
Elya Chen
STSiok Chin Teo
Siok Chin Teo
CJClarisse Jia Min Jang
Clarisse Jia Min Jang
WYWei Peng Yong
Wei Peng Yong
Background: Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) is a novel laparoscopic intraperitoneal chemotherapy technique, with advantages such as homogeneous distribution of aerosol and deeper tissue penetration. Thus far, PIPAC oxaliplatin has been administered at an arbitrary dose of 92 mg/m 2 . Aim: We aim to determine the dose-related safety profile and tolerability of PIPAC oxaliplatin using an evidence-based approach. The secondary aim is to evaluate clinic-pathologic response and the pharmacokinetic profile. Methods: This is a phase I 3+3 dose escalation study for gastric and colorectal cancer with predominant peritoneal metastasis starting at a dose of 45 mg/m 2 . Safety is assessed according to Clavien-Dindo Classification and Common Terminology Criteria for Adverse Events (version 4.0). Clinico-pathologic response is assessed using the Peritoneal Regression Grading Score, Peritoneal Cancer Index, and Response Evaluation Criteria In Solid Tumour criteria (version 1.1). Pharmacokinetic analysis is performed using Inductively Coupled Plasma-Mass Spectrometry assay. This trial is registered on ClinicalTrials.gov (NCT03172416). Conclusions: This phase I study can provide the scientific basis to identify the optimal dose for PIPAC with oxaliplatin such that the benefits of this novel and promising intraperitoneal chemotherapy delivery technique can be maximized.

5 September 2018 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
GKGuowei Kim
Guowei Kim
CTChuen Seng Tan
Chuen Seng Tan
KTKah Wei Tan
Kah Wei Tan
SLSerene P. Y. Lim
Serene P. Y. Lim
JSJimmy B. Y. So
Jimmy B. Y. So
ASAsim Shabbir
Asim Shabbir